'Optimal' methotrexate improves outcomes in RA

AN optimal methotrexate regimen, in which the dose is ramped up if necessary, leads to much better clinical outcomes for patients with early rheumatoid arthritis (RA), a study shows.

Among real world patients with early disease from the French ESPOIR cohort, those put on optimal methotrexate were more than four times as likely to achieve remission and normal functioning at one year than those on lower doses of the drug, the authors said.

However, there was no difference between the two groups in radiographic progression over two years, they wrote in the Annals of the